SGLT2 inhibitors may prevent diabetes

Daniel V O'Hara^{1

2}, Meg J Jardine^{3

4}

Affiliations

¹ NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
² Royal North Shore Hospital, Sydney, New South Wales, Australia.
³ NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia. megj@ctc.usyd.edu.au.
⁴ Concord Repatriation General Hospital, Sydney, New South Wales, Australia. megj@ctc.usyd.edu.au.

Comment

Daniel V O'Hara et al. Nat Rev Nephrol. 2022 Apr.

. 2022 Apr;18(4):203-204.

doi: 10.1038/s41581-022-00541-8.

Daniel V O'Hara^{1

2}, Meg J Jardine^{3

4}

¹ NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
² Royal North Shore Hospital, Sydney, New South Wales, Australia.
³ NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia. megj@ctc.usyd.edu.au.
⁴ Concord Repatriation General Hospital, Sydney, New South Wales, Australia. megj@ctc.usyd.edu.au.

No abstract available

Comment on

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.
Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-Rotter R, Toto RD, Wheeler DC, McMurray JJV, Heerspink HJL; DAPA-CKD and DAPA-HF Trial Committees and Investigators. Rossing P, et al. Lancet Diabetes Endocrinol. 2022 Jan;10(1):24-34. doi: 10.1016/S2213-8587(21)00295-3. Epub 2021 Nov 29. Lancet Diabetes Endocrinol. 2022. PMID: 34856173

1. Nomura, S. et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53, 6355–6360 (2010). - DOI
1. Herrington, W. G. et al. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur. J. Heart Fail. 23, 1260–1275 (2021). - DOI
1. Rossing, P. et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 10, 24–34 (2022). - DOI
1. Inzucchi, S. E. et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care 44, 586–594 (2021). - DOI
1. Steven, S. et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13, 370–385 (2017). - DOI